Results 1 to 10 of 13

Thread: Geron to raise $40million selling common stock

Hybrid View

Previous Post Previous Post   Next Post Next Post
  1. #1

    Geron to raise $40million selling common stock

    http://www.geron.com/pressview.asp?id=786

    “In 2007, we will fund multiple trials of our telomerase inhibitor drug, GRN163L, and we anticipate initiating a clinical trial for our cancer vaccine,” said David Greenwood, Geron’s executive vice president and chief financial officer. “We are also on a path to a regulatory filing and clinical trial for TAT0002, our telomerase activator drug, for patients with HIV/AIDS. Finally, we expect to file an IND to treat spinal cord injury using therapeutic cells derived from human embryonic stem cells. We want to maintain a strong balance sheet as we progress to and through these and potentially other trials.”

  2. #2
    Senior Member
    Join Date
    Jun 2005
    Location
    Norway
    Posts
    17,427
    They have four months on them to do this now if they’ll still stick to first quarter of 2007.

  3. #3
    Senior Member Schmeky's Avatar
    Join Date
    Sep 2002
    Location
    West Monroe, LA, USA
    Posts
    3,416
    http://www.fda.gov/cder/regulatory/a...m#Introduction

    Once the IND is submitted, the sponsor must wait 30 calendar days before initiating any clinical trials. During this time, FDA has an opportunity to review the IND for safety to assure that research subjects will not be subjected to unreasonable risk.


    Leif,

    If indeed Geron files for the IND this month, raises the capital via the sale of stock, a purified scalable source of cells are ready for injection/implantation, clincal trial centers are established, and trained clinicians are ready, then this could happen in the first quarter of 2007.

    Geron is a heavy hitter, a real player, so I would think they have laid the ground work and now only have the IND to file, but this is an assumption on my part.

    We must keep in mind this is a phase I for acutes. If this trial follows normal protocol in the USA, it will take about 11 years to conclude.

    If this SCI treatment as well as the other Geron derived products prove successful, they could easily become the next MicroSoft.

  4. #4
    Senior Member
    Join Date
    Feb 2006
    Location
    Murrieta, Ca.
    Posts
    424

    Geron

    Let's wish them luck and support their efforts in any way we can. Acute treatments or not, if they are successful it will pave the way for more ESC trials hopefully for chronics.

  5. #5
    Senior Member spidergirl's Avatar
    Join Date
    Nov 2005
    Location
    Hollywood, CA
    Posts
    1,049
    Geron's oil machine is like a baby Donald Trump they are determined and are doing everything in their power to be on top. Acute's are first though. Tom Okarma will not accept NO for an answer...he's a mover and a shaker and hungry to win.

    They see big dollars....and they are capitalizing ASAP.

    However, the real winner is the chronic discovery because acute's become Chronics immediately.
    Last edited by spidergirl; 12-14-2006 at 08:51 PM.

  6. #6
    Donald Trump (fish lips) gets things done. I recall the skating rink in NY was not operating and the city was concerned it would not open for the holiday season. They had only been able to get promises of the work being done much too late. Trump took the task on, an had the ice skating rink open in a matter of days.

    There is much to be said about getting the job done.

    Bottomline

    Trump is not in the ice skating rink business. He didn't make it a life long project nor build into the process an intrastructure. He fixed the rink.

    Sometimes I feel cures are being used to build life long careers, societies, and support labs in institutions. When the bottomline should be a cure.

  7. #7
    Senior Member
    Join Date
    Jun 2005
    Location
    Norway
    Posts
    17,427
    Quote Originally Posted by Schmeky
    http://www.fda.gov/cder/regulatory/a...m#Introduction

    Once the IND is submitted, the sponsor must wait 30 calendar days before initiating any clinical trials. During this time, FDA has an opportunity to review the IND for safety to assure that research subjects will not be subjected to unreasonable risk.


    Leif,

    If indeed Geron files for the IND this month, raises the capital via the sale of stock, a purified scalable source of cells are ready for injection/implantation, clincal trial centers are established, and trained clinicians are ready, then this could happen in the first quarter of 2007.

    Geron is a heavy hitter, a real player, so I would think they have laid the ground work and now only have the IND to file, but this is an assumption on my part.

    We must keep in mind this is a phase I for acutes. If this trial follows normal protocol in the USA, it will take about 11 years to conclude.

    If this SCI treatment as well as the other Geron derived products prove successful, they could easily become the next MicroSoft.
    David. I think you could be right here as for the Microsoft comparison if this proves safety and improvements, it will also boost this kind of research and put SCI research in general high up on the agenda worldwide. By the way, I just spoke to one professor here right now, he called me about our current legislation ESCR process but he also mentioned Geron and also the research which this is based on, namely some of Hans Keirstead’s work. He said a team here is collaborating with Hans Keistead like I have mentioned before to you. This research team is headed by Professor Joel Glover and he suggested to me to take contact with Glover to discuss this. I will do so and like now I am the new editor of our national SCI magazine, thereby I will make an interview with Glover to have in the magazine, I will translate to English and post next year because our next magazine is not due for until April/March. That should not be a problem I guess, because I don’t believe the cure will be here in meantime

  8. #8
    Senior Member Schmeky's Avatar
    Join Date
    Sep 2002
    Location
    West Monroe, LA, USA
    Posts
    3,416
    Leif,

    Congratulations on your appointment as the Editor for the SCI publication, I am confident you will do an excellent job. It's also good to know there is some collaboration taking place. I'm glad researchers like Kierstad are in the SCI arena.

  9. #9
    Senior Member Moe's Avatar
    Join Date
    Sep 2012
    Location
    Springfield
    Posts
    497
    12 years later.... where did that 40 million go?
    "Talk without the support of action means nothing..."
    ― DaShanne Stokes

    ***Unite(D) to Fight Paralyses***

  10. #10
    GOOGLE says: Geron stem cell assets were sold out to Asterias and that's where the stock went. If you owned Geron common stock, you now have Asterias common stock. Asterias is currently in SCI clinical trials. Geron worked on acute injuries and Asterias is doing sub-acute. (These aren't cells for chronic injury).

    Stock price: AST (NYSEAMERICAN) $1.50 +0.10 (+7.14%)
    Jul 6, 4:00 PM EDT


    https://www.sec.gov/Archives/edgar/d...0130-ex991.htm

    https://www.technologyreview.com/s/602350/after-setbacks-a-pioneering-stem-cell-technology-is-back-in-human-trials/
    Last edited by GRAMMY; 07-08-2018 at 07:20 PM.

Similar Threads

  1. Geron Corporation Announces the Pricing of Its Common Stock Offering
    By Wise Young in forum Funding, Legislation, & Advocacy
    Replies: 0
    Last Post: 09-16-2005, 02:54 PM
  2. Geron sells shares to raise $40 million
    By Jeremy in forum Cure
    Replies: 2
    Last Post: 11-12-2004, 04:23 PM
  3. NeoTherapeutics Reverse Stock split - 25:1
    By mk99 in forum Funding, Legislation, & Advocacy
    Replies: 4
    Last Post: 09-06-2002, 02:23 PM
  4. Replies: 2
    Last Post: 11-01-2001, 02:30 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •